OncoTherapy Science, Inc. (TYO:4564)

Market Cap	7.67B +21.0%
Revenue (ttm)	808.00M +7.7%
Net Income	-910.00M
EPS	-2.77
Shares Out	383.64M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140,658,100
Open	21.00
Previous Close	20.00
Day's Range	19.00 - 21.00
52-Week Range	18.00 - 35.00
Beta	0.26
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About OncoTherapy Science

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stag...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 47
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4564

Financial Performance

In fiscal year 2026, OncoTherapy Science's revenue was 808.00 million, an increase of 7.73% compared to the previous year's 750.00 million. Losses were -910.00 million, 11.7% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 24, 2026

Data Sources Report a data error